ClinicalTrials.gg
RecruitingNCT06286267Updated Feb 29, 2024

AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors

An observational study in Phyllodes Breast Tumor, Artificial Intelligence and Multiomics, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 4 sites in China. Open to female participants. Per ClinicalTrials.gov, last updated 2024-02-29.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
4,000
Sex
Female
01

Study summary

Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates.

In recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine.

The research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading.

The project has collected high-quality data from nearly a thousand breast PT patients, including imaging, histopathology, and survival data, and has performed transcriptome gene sequencing on tissue samples. They aim to build a comprehensive multi-omics database for breast PT and create an AI-based model for early diagnosis and prognosis prediction. This research has the potential to improve the diagnosis and treatment of breast PT, address the disparities in breast PT care across different regions in China, and contribute to the development of new therapeutic targets.

02

Conditions studied

  • Phyllodes Breast Tumor
  • Artificial Intelligence
  • Multiomics
  • Prognostic Cancer Model
  • Diagnosis

Browse trials for

03

In context

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are all those who attended Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with a phyllodes tumor of the breast

Exclusion criteria

Exclusion Criteria:

  • Blurred images, imaging artifacts
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Breast phyllodes tumor

    Patients diagnosed with phyllodes tumor of breast

    Diagnostic Test: imaging

Interventions

  • Diagnostic testimaging

    Patient medical imaging materials including ultrasound, mammography, CT, MRI

06

What researchers measure

Primary outcomes

  1. Sensitivity

    The probability of a positive test result, conditional on it being truly positive.

    Time frame: Five years

  2. False-negative Rate

    Determine the odds of testing negative in a positive population.

    Time frame: Five years

  3. Specificity

    The probability of a negative test result conditional on a true negative.

    Time frame: Five years

  4. False-positive Rate

    Determine the odds of testing positive in a negative population.

    Time frame: Five years

  5. Receiver Operating Characteristic Curve

    The ROC curve is a curve based on a series of different dichotomous classifications (cut-off values or decision thresholds), with the rate of true positives (sensitivity) as the vertical coordinate and the rate of false positives (1-specificity) as the horizontal coordinate.

    Time frame: Five years

  6. Area under roc Curve

    AUC is defined as the area under the ROC curve enclosed with the axes, and the closer the AUC is to 1.0, the more authentic the assay is.

    Time frame: Five years

07

Study locations

4 of 4 sites recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510050, China
    Recruiting
    • Feng Ye, Prof.Dr. · Contact15914388994
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
    Recruiting
  • The Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510145, China
    Recruiting
    • Hui Mai, Prof.Dr. · Contact13925129112
  • Guangdong Maternal and Child Health Hospital
    Guangzhou, Guangdong 511400, China
    Recruiting
    • Yu Tan, Prof.Dr. · Contact13632356526
08

References and documents

Publications

  • Mishra SP, Tiwary SK, Mishra M, Khanna AK. Phyllodes tumor of breast: a review article. ISRN Surg. 2013;2013:361469. doi: 10.1155/2013/361469. Epub 2013 Mar 20. PubMed 23577269 ↗
  • Belkacemi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):492-500. doi: 10.1016/j.ijrobp.2007.06.059. Epub 2007 Oct 10. PubMed 17931796 ↗
  • Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019 Nov;16(11):703-715. doi: 10.1038/s41571-019-0252-y. Epub 2019 Aug 9. PubMed 31399699 ↗
  • van der Laak J, Litjens G, Ciompi F. Deep learning in histopathology: the path to the clinic. Nat Med. 2021 May;27(5):775-784. doi: 10.1038/s41591-021-01343-4. Epub 2021 May 14. PubMed 33990804 ↗
  • Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wahlby C, Hartman J, Rantalainen M. Improved breast cancer histological grading using deep learning. Ann Oncol. 2022 Jan;33(1):89-98. doi: 10.1016/j.annonc.2021.09.007. Epub 2021 Sep 29. PubMed 34756513 ↗
  • Chow ZL, Thike AA, Li HH, Nasir NDM, Yeong JPS, Tan PH. Counting Mitoses With Digital Pathology in Breast Phyllodes Tumors. Arch Pathol Lab Med. 2020 Nov 1;144(11):1397-1400. doi: 10.5858/arpa.2019-0435-OA. PubMed 32150458 ↗
  • Cheng CL, Md Nasir ND, Ng GJZ, Chua KWJ, Li Y, Rodrigues J, Thike AA, Heng SY, Koh VCY, Lim JX, Hiew VJN, Shi R, Tan BY, Tay TKY, Ravi S, Ng KH, Oh KSL, Tan PH. Artificial intelligence modelling in differentiating core biopsies of fibroadenoma from phyllodes tumor. Lab Invest. 2022 Mar;102(3):245-252. doi: 10.1038/s41374-021-00689-0. Epub 2021 Nov 24. PubMed 34819630 ↗
  • Kates-Harbeck J, Svyatkovskiy A, Tang W. Predicting disruptive instabilities in controlled fusion plasmas through deep learning. Nature. 2019 Apr;568(7753):526-531. doi: 10.1038/s41586-019-1116-4. Epub 2019 Apr 17. PubMed 30996348 ↗
  • Gong C, Nie Y, Qu S, Liao JY, Cui X, Yao H, Zeng Y, Su F, Song E, Liu Q. miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Cancer Res. 2014 Aug 15;74(16):4341-52. doi: 10.1158/0008-5472.CAN-14-0125. Epub 2014 Jun 30. PubMed 24980553 ↗
  • Nie Y, Chen J, Huang D, Yao Y, Chen J, Ding L, Zeng J, Su S, Chao X, Su F, Yao H, Hu H, Song E. Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation. Cancer Res. 2017 Jul 1;77(13):3605-3618. doi: 10.1158/0008-5472.CAN-16-2709. Epub 2017 May 16. PubMed 28512246 ↗

Individual participant data

Plan to share: No — no plan to make individual participant data available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Mar 1, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286267
Collaborators
Sun Yat-sen University, Peking University Shenzhen Hospital, Guangdong Provincial Maternal and Child Health Hospital, The Third Affiliated Hospital of Guangzhou Medical University
Responsible party
nieyan (Principal Investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Feb 29, 2024
Start date
Mar 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 29, 2024

Study contacts

Yan Nie, Prof.Dr.
Contact
nieyan7@mail.sysu.edu.cn
+86 020-81332587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion